Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.71 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.71 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.71 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.71 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.71 |
| ▸ | RAF1 | P04049 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7750462 | 1.00 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7750467 | 1.00 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL8002384 | 0.92 | MAPK14 (0.79) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL15946565 | 0.88 | MAPK14 (0.85) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL8484311 | 0.87 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7979995 | 0.86 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7748842 | 0.84 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7748844 | 0.84 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7991937 | 0.84 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL4025113 | 0.83 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5717100-A | Substituted imidazoles having anti-cancer and cytokine inhibitory activity | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |